Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
Status:
Not yet recruiting
Trial end date:
2022-11-18
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to test how much delgocitinib enters the body over a given time
period after application of delgocitinib cream in patients with moderate to severe hand
eczema.
Delgocitinib is a cream that suppresses specific processes in the body's response to diseases
like CHE, such as inflammation. Everyone in the trial will use delgocitinib cream.
The trial will last up to 7 weeks and there will be 6 visits and a phone call. There will be
a screening period of up to 4 weeks, a treatment period (with blood sampling) of 11 days and
a safety follow-up phone call 11 days after the last visit.